Novavax, Inc.’s forthcoming emergency use authorization request for NVX-CoV2373 could lead to the availability of a fourth COVID-19 vaccine in the US, but that alone is unlikely to trigger a rethinking by the Food and Drug Administration as to how much longer to keep the EUA pathway open.
On 31 December, the company said it had completed submission of the chemistry, manufacturing and controls portion of the data...







